Advantest Corporation (TSE: 6857, NYSE: ATE) today announced that its
terahertz spectroscopic imaging system TAS7500, which utilizes
Advantest's THz wave technology, has been adopted by Astellas Pharma Inc.
The TAS7500 system enables non-destructive, contact-free spectroscopic
analysis and imaging of the inner structures of pharmaceutical products.
The system can analyze pharmaceuticals in liquid, powder or solid form,
and evaluate crystalline forms, chemical constituents, density, and
other characteristics. The system can also produce 2D and 3D images of
tablet coating layer thickness and density distribution, as well as
cross-sections of multi-layer tablets.
Pharmaceutical firms are developing increasingly complex products,
including the recent development of multi-layer tablets that deliver
active ingredients more effectively. Manufacturers face a serious
challenge in the speedy analysis of the crystalline forms and chemical
constituents of promising pharmaceutical materials. The spectroscopic
analysis and imaging functions offered by the TAS7500 enable fast,
simple, high-throughput drug analysis that contributes to speedier R&D